QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, announced that it has initiated a second Phase 3 clinical trial of Ophena(TM) (ospemifene tablets), the company’s estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

More: continued here

This entry was posted on Monday, September 8th, 2008 at 10:09 am and is filed under Clinical Trials. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.